NCT04339140View on ClinicalTrials.gov

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

Zafirlukast

Oral tablets, 2x daily for 28 day cycle up to 1 year

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT04339140 - Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer | Biotech Hunter | Biotech Hunter